Corindus Vascular Robotics Inc (CVRS) 1.41 $CVRS
Corindus Vascular Robotics (CVRS) Jumps: Stock Up 8.3%
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:00AM CDT
Corindus Vascular Robotics Inc. (CVRS) was a big mover last session, as the company's shares rose over 8% on the day.
CVRS: 1.41 (-0.03), CRY: 12.03 (+0.15)
Worcester Polytechnic Institute Professor to Highlight Surgical Robotics at Robotica 2016
PRWeb - Mon Jun 06, 2:01PM CDT
A Worcester Polytechnic Institute (WPI) professor will be part of a three-person panel discussing advances in patient-treatment robotics systems at Robotica 2016, a robotics summit that will be held June 6-9 in Devens, Mass.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Announces Additions to Management Team
BusinessWire - Mon May 09, 3:20PM CDT
--Nora Dutta Named Vice President of Human Resources
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Reports First Quarter 2016 Results
BusinessWire - Thu May 05, 3:05PM CDT
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today reported financial results for the three months ended March 31, 2016.
CVRS: 1.41 (-0.03)
AMETEK (AME) Posts In Line Q1 Earnings, Misses Revenues
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:16PM CDT
AMETEK Inc.'s (AME) first quarter 2016 earnings of 57 cents per share matched the Zacks Consensus Estimate.
ATEC: 0.23 (+0.01), AME: 49.23 (+0.48), EW: 102.67 (+1.14), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics to Report First Quarter 2016 Financial Results on May 5, 2016
BusinessWire - Thu Apr 21, 3:20PM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the first quarter 2016 after the close of trading on Thursday, May 5, 2016. The Company's management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
CVRS: 1.41 (-0.03)
Will Corindus (CVRS) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 9:00AM CDT
As of late, it has definitely been a great time to be an investor in Corindus Vascular Robotics Inc. (CVRS)
CVRS: 1.41 (-0.03)
Dr. Martin Leon Accepts Executive Advisor Role with Corindus Vascular Robotics as External Consultant
BusinessWire - Tue Apr 19, 3:20PM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Martin Leon, MD, one of the preeminent thought leaders in the field of interventional cardiology, has joined the company as an external consultant and executive advisor.
CVRS: 1.41 (-0.03)
FDA Clears CorPath Robotic System for Use in Peripheral Vascular Intervention
BusinessWire - Tue Mar 29, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that the U.S. Food and Drug Administration has cleared the CorPath(R) System for use in peripheral vascular interventions. This is the third clearance for the CorPath System including the initial clearance for percutaneous coronary intervention (PCI) which was followed by a clearance for radial PCI in October 2015. This 510(k) clearance for peripheral intervention was based on results of a clinical trial known as the RAPID (Robotic-assisted Peripheral Intervention for Peripheral Artery Disease) Study conducted at Medical University Graz in Austria.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics (CVRS) in Focus: Stock Soars 10.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:35AM CDT
Corindus Vascular Robotics Inc. (CVRS) was a big mover last session, as the company saw its shares surge over 10% on the day.
ABMD: 104.37 (+0.06), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Reports Fourth Quarter and Year End 2015 Results
BusinessWire - Tue Mar 08, 3:05PM CST
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today reported financial results for the three and twelve months ended December 31, 2015.
CVRS: 1.41 (-0.03)
Corindus names Campbell Rogers, MD to board
M2 - Tue Feb 09, 5:33AM CST
Medical device company Corindus Vascular Robotics (NYSE MKT:CVRS) revealed on Monday the addition of Campbell Rogers, MD to its board of directors with immediate effect.
CVRS: 1.41 (-0.03)
Corindus Launches CorPath Robotic-Assisted Coronary Intervention Program to Increase Physician Safety at Massachusetts General Hospital
BusinessWire - Tue Jan 05, 7:00AM CST
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) today announced the launch of a CorPath(R) robotic-assisted coronary intervention program at Massachusetts General Hospital ("MGH"
and the installation of its first CorPath System. Involvement in the robotic-assisted coronary intervention program will allow physicians at MGH to perform percutaneous coronary interventions (PCI) using the CorPath System while protected from radiation exposure in the system's radiation-shielded control cockpit.
CVRS: 1.41 (-0.03)
Edward Heart Hospital Leads Chicago Area with Use of CorPath(R) System for Robotic-Assisted Vascular Procedures
BusinessWire - Wed Dec 16, 3:10PM CST
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Edward Heart Hospital has become the first facility in the state of Illinois to perform procedures with the CorPath System, the first FDA-cleared medical device for robotically-assisted percutaneous coronary interventions (PCI).
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics to Participate in Upcoming Investor Conferences
BusinessWire - Mon Nov 09, 5:33PM CST
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today announced that the Company will be participating in two upcoming investor conferences.
CVRS: 1.41 (-0.03)
Most Recent Happenings in the Market - Research on Pharol SGPS, Corindus Vascular Robotics, Nuveen Floating Rate Income Opportunity Fund and THL Credit
ACCESSWIRE - Thu Nov 05, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 05, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharol SGPS S.A. (OTC: PTGCY), Corindus Vascular Robotics Inc. (NYSE: CVRS), Nuveen Floating Rate Income Opportunity Fund (NYSE: JRO) and THL Credit Inc. (NASDAQ: TCRD). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TCRD: 10.86 (-0.06), JRO: 10.61 (unch), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics and Mayo Clinic Launch Vascular Robotic Program to Research Physician Safety
BusinessWire - Mon Oct 12, 7:00AM CDT
Corindus Vascular Robotics (NYSE MKT: CVRS) today announced the formation of a joint robotic-assisted percutaneous coronary intervention (PCI) research and clinical program. The program utilizes the company's CorPath(R) System, the first and only FDA-cleared medical device to provide robotic-assisted precision to coronary PCI procedures while protecting hospital employees from occupational radiation exposure and orthopedic stress and strain.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics, Inc. names Gary Lickovitch Vice President of Sales and Service
BusinessWire - Thu Oct 08, 7:00AM CDT
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, announced today that it named Gary Lickovitch as Vice President of Sales and Service effective October 5, 2015. Mr. Lickovitch will report directly to Corindus' President and CEO, David Handler.
BSX: 22.80 (+0.17), ABT: 38.91 (-0.02), BCR: 225.01 (+2.36), CVRS: 1.41 (-0.03)
FDA Clears CorPath(R) System for Robotic-assisted Radial Access PCI Procedures
BusinessWire - Tue Oct 06, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that the U.S. Food and Drug Administration has given 510(k) clearance for its robotic-assisted CorPath System to be used during percutaneous coronary interventions (PCIs) performed via radial access. The 510(k) clearance was based on results of a clinical trial conducted at Spectrum Health, Grand Rapids, Mich., and St. Joseph's Hospital Health Center, Syracuse, N.Y., with an enrollment of 30 patients that demonstrated 100 percent device and clinical success.
CVRS: 1.41 (-0.03)
Leading Interventional Cardiologists to Discuss CorPath(R) System's Role in Physician Radiation Reduction and Procedural Precision in Complex and Radial PCI at TCT 2015
BusinessWire - Mon Oct 05, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] announced today that renowned interventional cardiologists will highlight their use of the CorPathSystem through presentations and poster sessions during the upcoming TCT 2015 meeting, Oct. 11-15, in San Francisco. Physicians will present their experience using the CorPath System during PCI procedures to demonstrate the radiation reduction that it provides.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics (CVRS) Jumps: Stock Up 8.3%
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:00AM CDT
Corindus Vascular Robotics Inc. (CVRS) was a big mover last session, as the company's shares rose over 8% on the day.
CVRS: 1.41 (-0.03), CRY: 12.03 (+0.15)
Worcester Polytechnic Institute Professor to Highlight Surgical Robotics at Robotica 2016
PRWeb - Mon Jun 06, 2:01PM CDT
A Worcester Polytechnic Institute (WPI) professor will be part of a three-person panel discussing advances in patient-treatment robotics systems at Robotica 2016, a robotics summit that will be held June 6-9 in Devens, Mass.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Announces Additions to Management Team
BusinessWire - Mon May 09, 3:20PM CDT
--Nora Dutta Named Vice President of Human Resources
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Reports First Quarter 2016 Results
BusinessWire - Thu May 05, 3:05PM CDT
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today reported financial results for the three months ended March 31, 2016.
CVRS: 1.41 (-0.03)
AMETEK (AME) Posts In Line Q1 Earnings, Misses Revenues
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:16PM CDT
AMETEK Inc.'s (AME) first quarter 2016 earnings of 57 cents per share matched the Zacks Consensus Estimate.
ATEC: 0.23 (+0.01), AME: 49.23 (+0.48), EW: 102.67 (+1.14), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics to Report First Quarter 2016 Financial Results on May 5, 2016
BusinessWire - Thu Apr 21, 3:20PM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the first quarter 2016 after the close of trading on Thursday, May 5, 2016. The Company's management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
CVRS: 1.41 (-0.03)
Will Corindus (CVRS) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 9:00AM CDT
As of late, it has definitely been a great time to be an investor in Corindus Vascular Robotics Inc. (CVRS)
CVRS: 1.41 (-0.03)
Dr. Martin Leon Accepts Executive Advisor Role with Corindus Vascular Robotics as External Consultant
BusinessWire - Tue Apr 19, 3:20PM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Martin Leon, MD, one of the preeminent thought leaders in the field of interventional cardiology, has joined the company as an external consultant and executive advisor.
CVRS: 1.41 (-0.03)
FDA Clears CorPath Robotic System for Use in Peripheral Vascular Intervention
BusinessWire - Tue Mar 29, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that the U.S. Food and Drug Administration has cleared the CorPath(R) System for use in peripheral vascular interventions. This is the third clearance for the CorPath System including the initial clearance for percutaneous coronary intervention (PCI) which was followed by a clearance for radial PCI in October 2015. This 510(k) clearance for peripheral intervention was based on results of a clinical trial known as the RAPID (Robotic-assisted Peripheral Intervention for Peripheral Artery Disease) Study conducted at Medical University Graz in Austria.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics (CVRS) in Focus: Stock Soars 10.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:35AM CDT
Corindus Vascular Robotics Inc. (CVRS) was a big mover last session, as the company saw its shares surge over 10% on the day.
ABMD: 104.37 (+0.06), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics Reports Fourth Quarter and Year End 2015 Results
BusinessWire - Tue Mar 08, 3:05PM CST
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today reported financial results for the three and twelve months ended December 31, 2015.
CVRS: 1.41 (-0.03)
Corindus names Campbell Rogers, MD to board
M2 - Tue Feb 09, 5:33AM CST
Medical device company Corindus Vascular Robotics (NYSE MKT:CVRS) revealed on Monday the addition of Campbell Rogers, MD to its board of directors with immediate effect.
CVRS: 1.41 (-0.03)
Corindus Launches CorPath Robotic-Assisted Coronary Intervention Program to Increase Physician Safety at Massachusetts General Hospital
BusinessWire - Tue Jan 05, 7:00AM CST
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) today announced the launch of a CorPath(R) robotic-assisted coronary intervention program at Massachusetts General Hospital ("MGH"
and the installation of its first CorPath System. Involvement in the robotic-assisted coronary intervention program will allow physicians at MGH to perform percutaneous coronary interventions (PCI) using the CorPath System while protected from radiation exposure in the system's radiation-shielded control cockpit. CVRS: 1.41 (-0.03)
Edward Heart Hospital Leads Chicago Area with Use of CorPath(R) System for Robotic-Assisted Vascular Procedures
BusinessWire - Wed Dec 16, 3:10PM CST
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Edward Heart Hospital has become the first facility in the state of Illinois to perform procedures with the CorPath System, the first FDA-cleared medical device for robotically-assisted percutaneous coronary interventions (PCI).
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics to Participate in Upcoming Investor Conferences
BusinessWire - Mon Nov 09, 5:33PM CST
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today announced that the Company will be participating in two upcoming investor conferences.
CVRS: 1.41 (-0.03)
Most Recent Happenings in the Market - Research on Pharol SGPS, Corindus Vascular Robotics, Nuveen Floating Rate Income Opportunity Fund and THL Credit
ACCESSWIRE - Thu Nov 05, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 05, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharol SGPS S.A. (OTC: PTGCY), Corindus Vascular Robotics Inc. (NYSE: CVRS), Nuveen Floating Rate Income Opportunity Fund (NYSE: JRO) and THL Credit Inc. (NASDAQ: TCRD). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TCRD: 10.86 (-0.06), JRO: 10.61 (unch), CVRS: 1.41 (-0.03)
Corindus Vascular Robotics and Mayo Clinic Launch Vascular Robotic Program to Research Physician Safety
BusinessWire - Mon Oct 12, 7:00AM CDT
Corindus Vascular Robotics (NYSE MKT: CVRS) today announced the formation of a joint robotic-assisted percutaneous coronary intervention (PCI) research and clinical program. The program utilizes the company's CorPath(R) System, the first and only FDA-cleared medical device to provide robotic-assisted precision to coronary PCI procedures while protecting hospital employees from occupational radiation exposure and orthopedic stress and strain.
CVRS: 1.41 (-0.03)
Corindus Vascular Robotics, Inc. names Gary Lickovitch Vice President of Sales and Service
BusinessWire - Thu Oct 08, 7:00AM CDT
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, announced today that it named Gary Lickovitch as Vice President of Sales and Service effective October 5, 2015. Mr. Lickovitch will report directly to Corindus' President and CEO, David Handler.
BSX: 22.80 (+0.17), ABT: 38.91 (-0.02), BCR: 225.01 (+2.36), CVRS: 1.41 (-0.03)
FDA Clears CorPath(R) System for Robotic-assisted Radial Access PCI Procedures
BusinessWire - Tue Oct 06, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that the U.S. Food and Drug Administration has given 510(k) clearance for its robotic-assisted CorPath System to be used during percutaneous coronary interventions (PCIs) performed via radial access. The 510(k) clearance was based on results of a clinical trial conducted at Spectrum Health, Grand Rapids, Mich., and St. Joseph's Hospital Health Center, Syracuse, N.Y., with an enrollment of 30 patients that demonstrated 100 percent device and clinical success.
CVRS: 1.41 (-0.03)
Leading Interventional Cardiologists to Discuss CorPath(R) System's Role in Physician Radiation Reduction and Procedural Precision in Complex and Radial PCI at TCT 2015
BusinessWire - Mon Oct 05, 7:00AM CDT
Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] announced today that renowned interventional cardiologists will highlight their use of the CorPathSystem through presentations and poster sessions during the upcoming TCT 2015 meeting, Oct. 11-15, in San Francisco. Physicians will present their experience using the CorPath System during PCI procedures to demonstrate the radiation reduction that it provides.
CVRS: 1.41 (-0.03)
